Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Cardinal Health, Inc. CAH is scheduled to report fiscal second-quarter 2025 results on Jan. 30, before the opening bell. In ...

a distributor of at-home medical supplies for managing diabetes. In addition, Cardinal closed the $1.2 billion acquisition of Specialty Networks, which provides software, AI analytics and business ...

Cardinal Health gets downgraded to a hold, from my buy rating last February, agreeing with the Seeking Alpha quant system rating. While macro-level demand for medical supplies is expected to keep ...

Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals ...

Morgan Stanley analyst Erin Wright maintained a Buy rating on Cardinal Health (CAH – Research Report) today and set a price target of $136.00.

The company said the new DC will support its at-Home Solutions business and improve the delivery of medical supplies to ...

Cardinal Health (NYSE:CAH – Free Report) had its price objective hoisted by JPMorgan Chase & Co. from $132.00 to $142.00 in a ...

In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Hold rating on Cardinal Health (CAH – Research Report), with a ...

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery ...